Finding an effective treatment for chronic neurodegenerative disorders still represents an unmet goal. There is considerable evidence that such disorders represent a combination of genetic determinants and failure of neuroprotective mechanisms sparking a wider degree of interest in shedding light on the cellular changes responsible for these devastating disorders. Because of their role in survival or differentiation of developing neurons, as well as the recent discovery of their importance in regulating synaptic plasticity during adulthood, neurotrophic factors have been suggested as essential contributors of the etiology of neurodegenerative disorders. Alzheimer's disease (AD) is a complex, chronic, devastating disease that affects a high percentage of the population over 65 years of age. This review will focus on different pharmacological interventions that are currently in use or drugs under development, narrowing the therapeutic agents to those that interfere with the expression of the trophic factor brain-derived neurotrophic factor (BDNF), a molecule playing a pivotal role in synaptic plasticity and cognition. From these findings, it appears clear that BDNF is implicated in the mechanism of action of drugs that improve cognitive deficits in animal models of AD and in AD patients.
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Etiology of Alzheimer's disease
Alzheimer's disease (AD) is a chronic brain disorder associated with specific pathological changes resulting in neurodegeneration and in progressive development of dementia. Clinically, cognitive impairments are observed, whereas, pathologically, the formation of senile plaques, neurofibrillary tangles and loss of synaptic contacts occur. The slow, progressive but inexorable impairment in cognitive processes depends upon molecular changes taking place in different brain regions. Among the plethora of theories suggested to explain the etiology of the disease, neurotrophic factors play an important role.
brain-derived neurotrophic factor (BDNF). BDNF belongs to the family of neurotrophins and, through the interaction with its high-affinity receptor trk B, is important for the survival and maintenance of different types of neurons. Moreover, BDNF mediates synaptic plasticity and cognitive processes. 4 Mesulam 5 proposed that AD is due to failure of neuroplasticity, which causes loss of synaptic contacts and may lead to the neuropathological and clinical manifestations. With respect to AD, BDNF has been shown to promote survival and differentiation of basal forebrain cholinergic neurons. 6 Interestingly, in these neurons, BDNF stimulates the release of acetylcholine, a neurotransmitter known to be defective in AD patients. 7 These preclinical observations suggest that deficits of BDNF synthesis might participate in the deterioration of the cellular homeostasis that leads to AD.
Besides its well-established role in development and maintenance of forebrain neurons, behavioral evidence relates BDNF expression to cognitive performance (for a review, see Murer et al.
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). Minichiello et al. 8 have shown that forebrain-specific knockout of trk B leads to severe deficits in learning, confirming the pivotal role of BDNF-induced signaling in this brain district. These results suggest that, in order to improve cognition and thus attenuate AD symptomatology, BDNF needs to be selectively enhanced in the forebrain.
Implication of BDNF in AD: clinical evidence
Several lines of clinical evidence have shown that the expression of BDNF and its high-affinity receptor, trk B, is decreased in post-mortem brain regions from AD patients. [9] [10] [11] [12] [13] [14] Interestingly, Murer et al. 15 have demonstrated that neurons containing neurofibrillary tangles, a hallmark of the disease, do not show BDNF-immunoreactive material, whereas those neurons with no tangles instead display intense BDNF staining. A recent detailed analysis focused on the BDNF promoters showing a significant decrease in three human BDNF mRNA transcripts in AD patients with respect to agematched controls. In detail, transcripts 1-3 showed a marked decrease, whereas no significant differences were observed for the other transcripts. 16 Thus, although the mechanisms responsible for BDNF downregulation in AD patients are still far from being understood, these results reveal that the regulatory mechanisms and factors governing human BDNF expression may be subtly altered in a specific, transcript-dependent manner.
Implication of BDNF in AD: genetic evidence
Several lines of evidence have recently suggested that genetic factors contribute to the development of AD. Among the genes encoding proteins known to confer susceptibility to AD, BDNF is thought to represent a plausible candidate gene. Indeed the BDNF val 66 met polymorphism is important for memory-related processes in humans, 17 suggesting that such polymorphism could be a predisposing factor for AD. Genetic analyses performed in different laboratories worldwide provided, however, a rather confusing picture, with effects being inconsistent across studies, and arguing against the possibility that this polymorphism might be causally related to AD. In fact, an association between BDNF val 66 met polymorphism, or other polymorphisms, and AD was found by some authors, [18] [19] [20] [21] suggesting that BDNF gene variants are significant risk factors for the disease, whereas other groups failed to confirm these data. [22] [23] [24] [25] [26] Furthermore, Lee et al. 27 have recently shown that decreased levels of BDNF protein in AD are independent of BDNF polymorphisms. Thus, although intriguing, the evidence implicating BDNF gene polymorphism is not overwhelming and deserves further studies. However, the possibility exists that a combination of environmental and genetic factors may affect the pathway of BDNF synthesis, thus resulting in synaptic abnormalities that could affect cognitive processes, although such interplay is not fully understood. Among environmental factors, early in life adversities play a pivotal role in determining cognitive deterioration later in life. Lemaire et al. 28 have shown that prenatal stress is able to impair cognitive processes at adulthood. We have recently shown that BDNF expression is markedly lowered in the brain of prenatally stressed rats, 29 whereas Koo et al. 30 have demonstrated that the post-natal environment can counteract prenatal effects on cognitive ability, through upregulation of the neurotrophin. Altogether, these results suggest that cognitive impairment resulting from antenatal or early post-natal adversities might, at least in part, be related to reduced expression of the neurotrophin.
Exogenous administration of BDNF: pros and cons
As BDNF deficit has been observed in AD patients, it is possible to hypothesize that delivery of exogenous BDNF might represent a valuable therapeutic approach for the disease. However, supplementation of exogenous BDNF suffers from different problems. The main problem related to exogenous delivery of BDNF depends on the amount of BDNF that reaches the affected neuron, as BDNF does not readily cross the blood-brain barrier. 31, 32 If such amount is too low, it might not be sufficient to produce the desirable effects, whereas, if it is too high, it might be paradoxically dangerous, as it might cause, for example, trk B receptors to downregulate, thus reducing the intracellular machinery linked to BDNF. The proper delivery, that is, its selectivity of action, is also essential for the neurotrophin to produce beneficial effects. To date, it has been difficult to overcome problems related to the selectivity of BDNF action, as only specific brain regions suffer from decreased BDNF expression, and flooding of BDNF in the brain is rather undesirable. In fact, an indiscriminate overload of BDNF in the brain might cause several problems related to neuronal excitability: to this end, it has been demonstrated that BDNF increases neuronal excitability and can exacerbate seizure development. 33 Similarly, Scharfman et al. In an attempt to overcome such delivery problems, different methods have been developed, which, however, did not solve the problem. In fact, the possibility exists to supplement BDNF through engineered cells that overexpress BDNF or, alternatively, to use viral vectors in order to appropriately vehicolate the neurotrophin. Another possibility is represented by transplants of fibroblasts genetically modified to secrete BDNF into the degenerated site. This approach has been used with success in rats with spinal cord lesion: encapsulation of genetically modified fibroblasts may be an effective strategy for delivering therapeutic products to the injured spinal cord; 35 however, the different nature of the neurodegenerative process (acute for the spinal cord lesion versus chronic for AD) does not allow one to make predictions about the suitability of this technique for AD. A successful attempt has been made to combine biocompatible polymers with fibroblasts that are genetically engineered to produce BDNF to ameliorate the optic tract of injured animals 36 or bladder and hindlimb function following spinal contusion in rats. 37 These methods should supply BDNF locally, an essential prerequisite of a therapy with the neurotrophin. However, we have to take into account that similar options have not been proved in humans affected by AD.
The aim of the present study is, thus, to review data supporting the possibility of modulating endogenous BDNF as an alternative option to ameliorate cognitive processes that are compromised during the course of AD.
The main advantage of such approach is that BDNF expression will be selectively increased in those brain regions where it is indeed reduced because of the ongoing neurodegenerative process, without flooding of the neurotrophin in different brain regions, as in the case of the exogenous supply of the neurotrophin. It is expected that such an approach will not only improve the clinical outcome because of the enhanced region selectivity, but it will also reduce the side effects inherent to exogenous BDNF administration.
Pharmacotherapy of AD: focus on BDNF modulation
Cholinergic drugs Nowadays, drugs activating cholinergic neurotransmission (donepezil, rivastigmine, galantamine) are the prevailing therapeutic approach used in AD patients, although their effects are limited and transient. Cholinergic agonists, which interact with postsynaptic cholinergic receptors, or cholinesterase inhibitors, whose actions highly depend upon the integrity of presynaptic neurons, are not effective in severe AD, which is characterized by a widespread loss of synapses. Interestingly, no evidence has been published so far on the effect of these drugs on BDNF expression, suggesting that they may produce transient and variable effects because of the limited ability to activate intracellular signaling cascades, a mechanism that produces longer lasting and stable changes on synaptic functions. Recently, Seo and Isacson 38 have shown that muscarinic cholinergic M1 agonists paradoxically increase synaptic amyloid precursor protein APP total levels and did not improve cognition. As stimulation of cholinergic neurotransmission is only palliative, new strategies should increase neuronal survival by attenuating their degeneration.
Glutamatergic drugs
A recent, interesting option is represented by memantine, a non-competitive inhibitor of ionotropic glutamate NMDA receptors that interacts with these receptors only when the channel is open, thus blocking glutamate-induced neurotoxicity with limited interference with the physiological actions of the neurotransmitter, which are essential for cognition (for a review, see Sonkusare et al. 39 ). Memantine is commercially available in Europe and United States for treating moderate to severe AD. 40 The drug possesses antioxidant properties but the effect on neurodegeneration seems to rely, at least in part, on modulation of BDNF expression. Marvanova et al. 41 have demonstrated that memantine at a clinically relevant dose that renders the drug devoid of many of the side effects associated with highaffinity NMDA channel blockers markedly increased the neurotrophin mRNA levels in different brain regions. Interestingly, memantine was able to enhance also the expression of the BDNF receptor, trk B, thus influencing the whole machinery responsible for BDNF signal propagation. These findings suggest that the neuroprotective properties of memantine might, at least in part, be mediated by its capacity to increase the endogenous production of BDNF in the brain. Because, as stated above, memantine is the only drug commercially available worldwide for the symptomatic cure of severe AD, the effects of memantine on BDNF expression provide a strong rationale for the development of other drugs with similar properties.
AMPA receptor modulators might represent a novel and different approach to treat cognitive dysfunctions. The rationale for their use relies on the potentiation of glutamatergic synaptic transmission that contributes to cognitive functions. These compounds belong to four groups: pyrrolidones (aniracetam), benzothiazides (cyclothiazides), benzylpiperidines also called ampakines (CX546) and biarylpropylsulfonamides (LY392098). Interestingly, ampakines and biarylpropylsulfonamides share the common property of increasing BDNF expression, as shown by several independent preclinical studies, further pointing to the putative therapeutic value of increased BDNF availability. [42] [43] [44] Lauterborn et al. 42 observed a marked increase in BDNF expression in forebrain neurons exposed to two AMPA receptor-modulating drugs (ampakines), CX614 and CX546. These results were corroborated by in vivo experiments demonstrating that chronic intraperitoneal injection of CX546 increased hippocampal BDNF mRNA levels. A potential problem related to ampakines administration is that BDNF becomes refractory to induction, 42 as a consequence of long-term use. The same authors have, however, demonstrated that spaced ampakine treatments Implication of BDNF in AD F Fumagalli et al might induce sustained elevation of BDNF levels, thus obviating the refractory state. 45 Legutko et al. 43 examined the effect of the biarylpropylsulfonamide AMPA receptor potentiator LY392098 on BDNF expression in primary neurons. This compound robustly elevated the neurotrophin expression, an effect that seems to be restricted to forebrain neurons, whereas cerebellar granule cells display a more modest induction. Chronic systemic injection of another biarylpropylsulfonamide, LY451646, produced a significant increase of hippocampal BDNF expression as well as of its high-affinity receptor trk B. 44 Interestingly 48 ). So far, these compounds seem to have a positive impact on the memory of young individuals 49 as well as of elderly subjects, 50 enhancing their cognitive function. Thus, the possibility exists that chronic treatment with AMPA potentiators, in part by upregulating BDNF expression in forebrain regions, may offset abnormalities in brain functions and ameliorate cognitive capabilities in AD patients.
Estrogens
A great wealth of information has recently been generated with respect to the use of estrogens in the therapy of AD. Accumulating evidence from both preclinical and clinical studies has suggested that estrogens exert a neuroprotective action in the brain through different mechanisms 51, 52 and might modulate specific cognitive functions. 53 Whereas administration of estrogens might represent a promising therapeutic approach for the disease, some studies have recently challenged this hypothesis, suggesting that such therapy might instead be harmful for those patients. 54, 55 Brinton 55 as well as Li and Shen 56 propose that the time at which estrogen therapy begins and the neurological situation of the brain at that time are crucial factors to determine the benefits of such therapy; for this reason, we cannot rule out the possibility that such therapy could effectively prevent AD by promoting cellular resilience to damage and interrupting the processes leading to cognitive alterations: these goals may be achieved through direct enhancement of cholinergic neuron function by estrogens 57 or, indirectly, by enhancing BDNF expression. This possibility is substantiated by the observation that an estrogen response element is present in the BDNF gene, corroborating the link between estrogens and the neurotrophin. 58 Estrogens increased BDNF expression during development 59 as well as during adulthood [60] [61] [62] in the forebrain, an effect that could enhance and maintain an appropriate functional status of the neurons, which degenerate in AD. These results also suggest that estrogens might improve AD symptoms, at least partly, by upregulating BDNF expression. 63 However, owing to the wide-ranging spectrum of actions exerted by estrogens, estrogen therapy is not recommended as monotherapy and further studies are needed to clearly establish the role of estrogens in AD.
Cannabinoids
Among the strategies that might be employed in order to prevent or oppose the ongoing neurodegenerative process in AD, cannabinoids may represent a fruitful opportunity. These substances are known to provide neuroprotection in a variety of experimental conditions including excitotoxicity, hypoxia and cerebral ischemia. 64, 65 Ramirez et al. 66 have recently shown that cannabinoids succeed in preventing the neurodegeneration occurring in AD, by blocking microglial activation. The neuroprotective action of cannabinoids was confirmed in vitro by Iuvone et al., 67 who exposed PC12 cells to b-amyloid peptide causing marked cell death as a consequence of increased formation of reactive oxygen species, increased lipid peroxidation and DNA fragmentation. Prior exposure to cannabidiol, a major non-psychoactive component of the marijuana plant, elevated cell survival by reducing production of reactive species as well as by attenuating DNA fragmentation and lipid peroxidation. 67 Interestingly, Butovsky et al. 68 have demonstrated that chronic exposure to D9-tetrahydrocannabinol markedly upregulates BDNF expression in different brain regions. It is thus possible to speculate that cannabinoids oppose neurodegeneration through alternative ways, implicating direct effect on cell survival and long-term effect on determinants of synaptic plasticity and adaptive processes underlying cognition. Because of these features, it is possible to suggest that cannabinoids may result effective in preventing or mitigating the neurodegenerative process occurring in AD.
GABA-B antagonists
Among the drugs that are currently being tested in clinical trials for AD, Froestl et al. 69 have illustrated the potential of the GABA B receptor antagonist SGS742. In a Phase II doubleblind, placebo-controlled study in 110 patients characterized by mild cognitive deficits, repeated administration of SGS742 significantly improved attention and working memory. 69 These clinical findings are supported by preclinical studies showing that the GABA B receptor antagonist displays pronounced cognitive enhancing effects in rats involved in different learning tasks. 70 These behavioral observations are paralleled by molecular experiments revealing that SGS742 significantly increased BDNF expression in frontal cortex and hippocampus. The neurotrophin expression was markedly increased when measured 24 h following the treatment, suggesting a putative molecular mechanism through which SGS742 might affect cognitive processes. Based on these preliminary preclinical and clinical observations, a second Phase II clinical trial in 280 AD patients is underway. 69 
Phosphodiesterase inhibitors
A further possibility to enhance BDNF expression is to regulate intracellular messengers that might regulate Implication of BDNF in AD neurotrophin production. In particular, sustained elevation of cAMP, via chronic administration of rolipram, a phosphodiesterase 4 (PDE4) inhibitor, increases the expression of BDNF as well as the phosphorylation of cAMP response element binding protein (CREB). 71 Such effect on BDNFdependent signal propagation may explain the persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model following chronic rolipram treatment. 72 The increase in BDNF expression is long-lasting, being still elevated 2 months after the end of the treatment. The potential therapeutic outcome of these compounds is underlined by the fact that novel PDE4 inhibitors are currently being developed by the pharmaceutical industry. 72 Finally, results obtained with rolipram suggest that compounds that potentiate the cAMP-dependent pathway may represent a promising therapeutic approach for the treatment of AD.
Lithium
Lithium is a small ion with a wide array of potential applications in disorders of the central nervous system. Historically, this drug represented, and still does, the therapy of choice for bipolar disorder. However, recent data raised the possibility that its action might be beneficial also for the treatment of AD. Su et al. 73 reported that lithium inhibits b-amyloid peptide production in HEK293 cells and in the hippocampus of a mouse model of AD. It is suggested that such action of lithium is mediated via inhibition of glycogen synthase kinase-3b (GSK3b): in fact, use of antisense oligonucleotide against GSK3b reduces b-amyloid peptide production. Phiel et al. 74 obtained similar results in CHO cells and primary mouse neurons, although the effect was attributed to GSK3a. These results are corroborated by the observations of De Ferrari et al., 75 who showed that activation of Wnt signaling by lithium rescues neurodegeneration and behavioral impairments induced by b-amyloid fibrils. In line with these observations, Alvarez et al. 76 showed that lithium prevents the formation of tau hyperphosphorylation caused by aggregates of b-amyloid and consequent cell death in cultured neurons. B-amyloidinduced cell death was also shown in PC12 cells and cerebellar granule cells by Wei et al., 77 an effect that was reverted by chronic lithium administration. Thus, it is possible to state that several lines of evidence point to lithium as a novel therapeutic opportunity for AD. 78 Based on the above data, it appears clear that lithium indeed exerts a robust neuroprotective activity over a wide number of cellular phenotypes by interfering with different intracellular signaling pathways. 78, 79 Interestingly, among the different intracellular cascades, the activation of BDNF/trk B signaling pathway appears to play a crucial role for the neuroprotective effects of this drug, 80 suggesting that some neuroprotective properties of lithium could be ascribed to BDNF.
Peptides
Although BDNF seems to play an important role in the etiology and the therapeutic action of drugs used to treat cognitive symptoms of AD, it is worth noting that novel therapeutic approaches exist that do not imply, to date, any effect on the neurotrophin BDNF. However, whether these new treatments will be effective in AD remains to be established yet and we cannot rule out the possibility that, somehow in their action, these new approaches will impact the BDNF pathway. For example, innovative processes are under investigation, which involve the use of vaccine strategies against the amyloid-b peptide. However, clinical trials were halted owing to a significant occurrence of undesirable effects 81 although other studies in humans demonstrate that such approach may attenuate the progressive cognitive decline typical of the disease. 82 Interestingly, amyloid-b peptide, at sublethal concentrations, reduces BDNF activity in cultured cortical neurons causing increased vulnerability of neurons and suggesting that blocking amyloid-b peptide actions, through the use of the appropriate vaccine, thereby restoring appropriate BDNF biosynthesis, may provide a robust interference with ongoing degeneration and counteract, at least in part, the cognitive decline. 83 Recently, Faden et al. 84 have developed novel small peptides characterized by neuroprotective activities. Such peptides are analogs of the tripeptide thyrotropin-releasing hormone and display neuroprotective properties across animal models of trauma. In particular, the compound named 35b, which has been developed for clinical trials, improves cognitive processes when repeatedly administered to rats suffering from chronic traumatic brain injury. 84 Furthermore, 'in vitro' approaches using inducers of cell death such as b-amyloid confirm the neuroprotective activity of 35b. For these reasons, the authors conclude that these novel dipeptides, through their multipotential actions, may be attractive candidates for the therapy of chronic neurodegenerative disorders such as AD. 84 Interestingly, among the changes produced by the treatment with 35b at the hippocampal levels, Faden et al. 84 found that BDNF expression was upregulated as long as 72 h from the end of the treatment in traumatic brain-injured rats, further pointing to the importance of the neurotrophin as a key modulator of drug treatments putatively efficacious in chronic neurodegenerative disorders.
Lifestyle
The possibility to interfere with AD development by means of simple and challenging lifestyle changes may have implications for prevention of cognitive decline associated with AD. In line with this possibility, Lazarov et al. 85 have elegantly demonstrated that enriched environment results in a marked reduction of cerebral deposits of b-amyloid with respect to animals housed in standard conditions. This observation is in agreement with previous reports showing that b-amyloid production can be modulated by synaptic activity, 86 which is increased by enriched environment. Although it is difficult to dissect out the different components of environmental manipulations, we have to consider Implication of BDNF in AD that increased physical activity may play a role. In fact, it has recently been demonstrated that exercise attenuates bamyloid build-up 87 in a transgenic model of AD. This observation is in agreement with an epidemiologic study showing a markedly increased risk of developing cognitive deterioration in inactive patients 88 and with another report illustrating the protection exerted by physical activity against cognitive failure.
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Changes in lifestyle might imply also changes in food consumption. Thus, the possibility that diet might interfere with onset and development of AD has been considered. Luchsinger and Mayeux 90 have extensively reviewed the implications of dietary factors in AD. They conclude that, although epidemiological studies have investigated the relationship between diet and AD, the results are not clearly established. Only few trials have demonstrated the potential benefit of the micronutrient vitamin E in the prevention of AD, [91] [92] [93] [94] suggesting that inhibition of oxidative stress might be important in delaying AD onset. Post-mortem studies on the brains of AD patients revealed that markers of oxidative damage are indeed affected, such as increased lipid peroxidation or increased protein and DNA oxidation. 95 Although addressing the molecular mechanisms through which the environment may be acting in animal models of AD is not simple, it is interesting to point out that BDNF is a common denominator that accompanies the different changes in lifestyle above examined and their impact on cognition. In fact, Ickes et al. 96 have shown that rats raised in an enriched environmental condition perform better on a spatial memory task and display increased expression of BDNF in hippocampus and cerebral cortex. Similarly, Lazarov et al. 85 have demonstrated that BDNF is increased in animal models of AD characterized by reduced levels of bamyloid deposition. These findings raise the possibility that BDNF is a mediator of the benefits produced by enriched conditions in animal models of AD.
Examining the molecular basis of the improvement in cognition produced by physical activity, Vaynman et al. 97 were able to show that physical exercise enhanced cognitive functions through BDNF upregulation. BDNF appears to be involved also in the recovery of function following traumatic brain injury, 98 further indicating the pivotal role in mediating the beneficial effect of voluntary exercise. With respect to diet, among the epidemiological studies investigating correlations between food consumption and AD, only vitamin E was shown to be effective. [91] [92] [93] [94] Interestingly, vitamin E normalized the reductions in BDNF expression and CREB phosphorylation in the hippocampus produced by high-fat diet with concomitant amelioration of the cognitive functions. 99 These findings suggest that vitamin E dietary intake, probably acting by enhancing BDNF and CREB pathway, may represent an evolving therapeutic option for the diseases characterized by oxidative damage such as AD.
Conclusion
Several lines of evidence point to BDNF deficit as an important contributor to the pathogenesis of AD. Such impairment is mainly focused in forebrain regions, which are known to support cognitive functions, and suggest that the reversal of this deficit may contribute to amelioration of disease symptomatology.
Interestingly, drugs clinically used to fight AD as well as newly developed therapeutic interventions share the same, probably unintentional, property to modulate BDNF levels in brain regions directly involved in the pathophysiology of the disease. Although involuntary, the common feature to positively interfere with BDNF biosynthesis might represent an interesting characteristic to be studied for the development of new, more effective drugs. In this review, we emphasize that modulation of BDNF expression may provide a baseline to rationalize the research of targeted interventions, perhaps setting the stage for a more selective, high-throughput screening of novel compounds. We have also to take into account that modulation of endogenous BDNF might be more successful when neurons are not profoundly degenerated but still responsive to such changes, indicating that the timing of such modulation might be essential for such therapy.
Although it is difficult to indicate what it would take to develop BDNF-specific drugs, the identification of molecules that specifically regulate BDNF in particular cellular phenotypes might improve the efficacy of therapy against AD. Thus, the possibility to fine-tune BDNF expression in specific brain sites suffering from trophic deficit might allow a general refinement of the strategies to fight this devastating disorder.
